Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Cerity Partners LLC

Cerity Partners LLC lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 14.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 28,598 shares of the company’s stock after selling 4,786 shares during the period. Cerity Partners LLC’s holdings in Kiniksa Pharmaceuticals were worth $566,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $158,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Teacher Retirement System of Texas grew its stake in Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after buying an additional 719 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $258,000. Finally, New York State Common Retirement Fund lifted its stake in Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after buying an additional 1,680 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock opened at $20.05 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.87 and a one year high of $28.15. The company has a fifty day moving average of $21.07 and a 200-day moving average of $21.42. The stock has a market capitalization of $1.46 billion, a PE ratio of -143.20 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research reports. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $37.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 11,464 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $23.10, for a total value of $264,818.40. Following the completion of the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 32.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $20.48, for a total value of $245,760.00. Following the sale, the chief operating officer now directly owns 77,363 shares in the company, valued at $1,584,394.24. This trade represents a 13.43 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,766 shares of company stock valued at $2,002,135. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.